Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - Pharmaceutical Development - April 23, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/24/17 - Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017
By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017. The Company will host a conference call and webcast to discuss these results on Thursday, March 16, 2017 at 8:30 a.m. Eastern Time. About Aeter
3/24/17 - China looks to streamline drug approvals [T-break Tech (Middle East)]
At present, new drugs are often launched in China years after they are available in other countries. China is the worlds second-largest drug market but one where foreign firms have struggled with regulations on new products, according to the U.S. International Trade Administration. In addition, foreign manufacturers would not have to undertake...
3/24/17 - FDA Approves First-ever Merkel Cell Carcinoma Drug, HTGM Riding High, FLXN Soars
THOUSAND OAKS- The European Commission has approved Amgen's AMGEVITA as a biosimilar to Humira for the treatment of certain inflammatory diseases. AMGEVITA is Amgen's first biosimilar to be approved by the European Commission. AMGEVITA was approved in the United States by the FDA last September.
3/24/17 - FDA Approves Increased Shelf Life and In-Use Storage at Room Temperature for Orfadin nitisinone
By a News Reporter-Staff News Editor at Drug Week Sobi, a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families, announced that the FDA approved a supplemental new drug application for Orfadin capsules in the U.S. The sNDA will allow
3/24/17 - FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
OSAKA, Japan& FLORHAM PARK, N.J.& STAMFORD, Conn. Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration approved Symproic 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation in adult patients with chron
3/24/17 - FDA Approves Treatment for Metastatic Merkel Cell Carcinoma
The US Food and Drug Administration has granted accelerated approval for Bavencio (avenulab), a treatment for a rare and aggressive form of skin cancer called metastatic Merkel cell carcinoma (MCC).
3/24/17 - Genentech: Rituxan For Pemphigus Vulgaris Gets Breakthrough Therapy Designation
SOUTH SAN FRANCISCO- Genentech, a member of the Roche Group, announced Friday that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation status to Rituxan for pemphigus vulgaris. Genentech is currently enrolling a Phase III study in pemphigus vulgaris, a disease for which there are limited treatment options.
3/24/17 - Hutchison China Meditech Limited: Positive Fruquintinib Pivotal Phase III Results
By a News Reporter-Staff News Editor at Drug Week Hutchison China Meditech Limited. London: Friday, March 3, 2017: Hutchison China MediTech Limited announces top-line results from FRESCO, its Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer in China, who failed at least two
3/24/17 - Merck KGaA : FDA Approves First Treatment For Rare Form Of Skin Cancer
NEW YORK CITY- Merck KgaA and Pfizer Inc. announced that the US Food and Drug Administration has approved BAVENCIO or avelumab Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma or mMCC. BAVENCIO will be co-commercialized by EMD Serono, the biopharmace
3/24/17 - NanoBio Receives SBIR Grant For Genital Herpes Vaccine
By a News Reporter-Staff News Editor at Drug Week- HYPERLINK ""\ nNanoBio Corporation announced that it has been awarded a two-year Phase II Small Business Research Innovation grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for the development of an intranasa
3/24/17 - NuGlobal Healthcare, LLC: Founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades.
NuGlobal Healthcare, LLC is founded to innovate and revolutionize generic pharmaceutical industry using proprietary niche technologies and decades of value driven pharmaceutical experience to deliver quality drug products focusing patients unmet needs and affordability by de-risking and maximizing investor capital. NuGlobal Healthcare jointly...
3/24/17 - Patent Issued for Sustained Release Guanfacine HCL Formulation (USPTO 9585842)
By a News Reporter-Staff News Editor at Drug Week A patent by the inventors Tuereli, Akif Emre; Baumstuemmler, Bernd; Ammer, Richard, filed on April 28, 2014, was published online on March 7, 2017, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9585842 is assigned to SALMON PHARMA GMBH.
3/24/17 - Pfizer Receives Positive CHMP Opinion for Trumenba for Prevention of Meningococcal Group B Disease
Pfizer, a pharmaceutical company, issued the following news release:. Pfizer Inc. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending that TRUMENBA (R) be granted marketing authorization in the European Union for active immunization of individuals 10 years a
3/24/17 - PureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 Programs
PureTech Health plc, an advanced clinical stage biopharmaceutical company, today announced a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 pathway. PureTech Health will develop these new product candidates in an operating subsidiary, resTORbio, with an...
3/24/17 - Reports from Johns Hopkins University Bloomberg School of Public Health Add New Data to Findings in Hypertension (Antihypertensive medications and...
By a News Reporter-Staff News Editor at Insurance Weekly News New research on Cardiovascular Diseases and Conditions- Hypertension is the subject of a report. Our news journalists obtained a quote from the research from the Johns Hopkins University Bloomberg School of Public Health, "We used 2 datasets for our analysis. Our secondary cohort inclu
3/24/17 - Researchers at Jena University Hospital Release New Data on Chronic Myeloid Leukemia (Treatment-free remission following frontline nilotinib in...
By a News Reporter-Staff News Editor at Drug Week Current study results on Oncology- Chronic Myeloid Leukemia have been published. According to news reporting originating in Jena, Germany, by NewsRx journalists, research stated, "The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission following frontline nil
3/24/17 - Shires drug picked up from Baxalta given fast track designation [Sudan Tribune]
The drug was formerly known as BAX930 and was acquired as part of Shires mega-merger with Baxalta. Phase 1 results were posted by Baxalta back in May of 2016, revealing that 15 patients who were treated during the trial had suffered only minor adverse events that were resolved without the need of medication. Todays confirmation from FDA that SHP655
3/24/17 - Studies from University of Pittsburgh Have Provided New Data on Cancer Therapy (Comparing the Approval and Coverage Decisions of New Oncology Drugs...
Our news journalists obtained a quote from the research from the University of Pittsburgh, "To compare the approval and coverage decisions for new anticancer drugs between the United States and 4 other countries: the United Kingdom, France, Australia, and Canada. Of 45 anticancer drug indications approved in the United States between January 1, 200
3/24/17 - Surgery Without the Knife: Mirabilis Medical Announces European Approval for Non-Invasive Uterine Fibroid Treatment
Mirabilis Medical, a Seattle- area developer of advanced medical technology for non-invasive surgery, announced today CE Mark authorization for marketing of the Mirabilis System for treatment of uterine fibroids throughout the European Union. The company simultaneously announced that it had received approval from the US Food and Drug Administrati
3/24/17 - Teewinot Life Sciences Corporation's Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad...
Teewinot Life Sciences Corporation's Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids. By a News Reporter-Staff News Editor at Drug Week- Teewinot Life Sciences Corporation, a global leader in development of cannabinoid-based pharmaceutica
3/24/17 - Teligent, Inc. Announces FDA Approval Of Clobetasol Propionate Gel, 0.05%
By a News Reporter-Staff News Editor at Drug Week Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced it has received approval of the Company's abbreviated new drug application from the U.S. Food and Drug Administration of Clobetasol Propionate Gel, 0.05%. This is Teligent's second approval for 2017, and its th
3/24/17 - Vertos Medical's mild Procedure Receives Broad Coverage From Centers For Medicare & Medicaid Services
By a News Reporter-Staff News Editor at Insurance Weekly News- Vertos Medical, a medical device company committed to developing innovative, minimally invasive treatments for lumbar spinal stenosis, has received national coverage for its mild Procedure through a recently approved study under the Centers for Medicare& Medicaid Services' Coverage
3/24/17 - Xenetic Biosciences to Present at the 29th Annual ROTH Conference
By a News Reporter-Staff News Editor at Drug Week Xenetic Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced that M. Scott Maguire, Xenetic's Chief Executive Officer will present at the 29th Annual ROTH
3/24/17 - Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, today reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for the treatment of moderate to severe facial acne..
3/23/17 - Aeglea BioTherapeutics to Present Topline Data fromPhase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancers, today announced topline data from a Phase 1 open-label study evaluating the safety and tolerability of its lead product candidate, AEB1102, for patients with Argi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement